Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · Real-Time Price · USD
41.28
+1.28 (3.20%)
Jan 21, 2025, 4:00 PM EST - Market closed
Ultragenyx Pharmaceutical Employees
Ultragenyx Pharmaceutical had 1,276 employees as of December 31, 2023. The number of employees decreased by 35 or -2.67% compared to the previous year.
Employees
1,276
Change (1Y)
-35
Growth (1Y)
-2.67%
Revenue / Employee
$409,675
Profits / Employee
-$438,078
Market Cap
3.81B
Employees Chart
Employees History
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 89,900 |
| Novartis AG | 76,057 |
| Merck & Co. | 72,000 |
| Novo Nordisk | 64,319 |
RARE News
- 4 days ago - Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 days ago - Ultragenyx's Multiple Commercial Assets And Candidates Impress Analyst; Sees Solid Upside - Benzinga
- 9 days ago - Ultragenyx Reports Preliminary 2024 Revenue, Financial Guidance for 2025, Pipeline Updates, and 2025 Milestones - GlobeNewsWire
- 15 days ago - Ultragenyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 15 days ago - European Commission (EC) Extends the Approval of Evkeeza® (evinacumab) to Children as Young as 6-months Old with Homozygous Familial Hypercholesterolemia (HoFH) - GlobeNewsWire
- 4 weeks ago - NHS England Rolls Out Evkeeza® ▼(evinacumab) for Eligible Adults and Adolescents Aged 12 Years and Older with Homozygous Familial Hypercholesterolaemia (HoFH) - GlobeNewsWire
- 4 weeks ago - Ultragenyx Announces First Patient Dosed in Pivotal Phase 3 Aspire Study Evaluating GTX-102 in Angelman Syndrome - GlobeNewsWire
- 2 months ago - Ultragenyx to Participate in Investor Conferences in December - GlobeNewsWire